News · Longevity & Aging
Semaglutide started late in life extended lifespan in female mice and matched calorie restriction
Weight-loss drugs keep producing benefits nobody designed them for. Giving semaglutide to 20-month-old mice, roughly late middle age for a mouse, slowed several measures of aging and extended life.
- This was done in mice, and nothing here has been tested in people.
- Treatment began at 20 months, which is late middle age for a mouse.
- Treated animals held onto physical function and lived longer.
- On memory, curiosity and glucose control they beat calorie restriction.
- Only female mice were followed for lifespan.
Start here, because it governs everything that follows: this was done in mice. Not in people, not in a trial, not in anybody you know taking the drug for their weight.
With that established, the result is genuinely interesting.
How semaglutide was given to 20-month-old mice
Writing in Nature, researchers gave semaglutide to female mice aged 20 months. A laboratory mouse of that strain typically lives somewhere between 24 and 30 months, so this is roughly the equivalent of starting a treatment in late middle age.
That timing is the first thing worth noticing. The long catalogue of interventions that extend mouse lifespan is dominated by things started in young animals, which is scientifically tidy and close to useless as a model for anyone already old.
What happened to the treated mice
The treated animals held onto physical function that their untreated counterparts lost. Several of the cellular changes that accumulate with age were attenuated, and the nutrient-sensing machinery that governs aging in everything from yeast upward shifted.
Then, with treatment continued, they lived longer.
How semaglutide compared against calorie restriction
Calorie restriction is the benchmark. Eating substantially less extends life in laboratory animals more reliably than anything else, and every candidate intervention is measured against it.
The researchers ran both side by side. Semaglutide recapitulated many functional benefits of calorie restriction, and on three measures it did better: exploratory drive, spatial memory and glucose control.
That last part is the striking claim. A drug producing more favourable trajectories than the intervention it is being compared to is not what usually happens.
Why an appetite drug could mimic calorie restriction
Semaglutide makes an animal eat less. Calorie restriction makes an animal eat less. If the mechanism behind calorie restriction is largely about reduced nutrient intake and the sensing pathways that respond to it, a drug that suppresses appetite is doing a chemical version of the same thing.
The study found exactly that signature: the nutrient sensors and conserved genetic regulators of aging moved in the directions calorie restriction moves them.
So this is not a mysterious new longevity mechanism. It is a plausible route to an old one, taken by people who find the old one impossible to sustain.
Why mouse lifespan says little about human lifespan
Mice are not small people. The history of aging research is a graveyard of compounds that extended rodent lifespan and did nothing in humans, and the failure rate is high enough that mouse lifespan data is treated as a reason to investigate rather than a reason to believe.
Only females were followed for lifespan. Aging interventions in mice routinely work in one sex and not the other, so this is a gap rather than a footnote.
And the drug is not free of consequence. Semaglutide causes nausea, and in older people it causes muscle loss alongside fat loss, which is precisely the wrong trade for someone already losing muscle to age.
What the semaglutide result is actually good for
Making healthy choices can help you stay healthy as you age, and there is currently no drug that has been shown to slow human aging.
What this result does is make a specific, testable claim worth pursuing: that appetite-suppressing drugs may reach the nutrient-sensing pathways that calorie restriction reaches, late in life, without requiring anyone to be hungry. Testing that in humans would take decades and the trials do not exist.
Anyone reading this as a reason to seek the drug for longevity is reading a mouse study as a prescription.
People also ask
What did the study find?
Treating 20-month-old female C57BL/6 mice with semaglutide for three months improved physiological function, attenuated hallmarks of aging and modulated nutrient sensors and conserved genetic regulators of aging. Continued treatment extended mouse lifespan. Against matched calorie restriction, semaglutide produced more favourable trajectories in exploratory drive, spatial memory and glucose control.
Does this apply to people?
No. This is a mouse study, and mouse lifespan results have a long history of not carrying across to humans. Nothing here is evidence that semaglutide extends human life, and no trial has tested that.
Why start treatment at 20 months?
Because it is late. A C57BL/6 mouse typically lives around 24 to 30 months, so 20 months is roughly late middle age. Most interventions that extend mouse lifespan are started young, which makes them far less relevant to anyone already old.
What is calorie restriction?
Eating substantially less without becoming malnourished. It is the most reliably reproduced way of extending lifespan in laboratory animals, and it is the benchmark any candidate anti-aging intervention gets measured against.
What does it mean to match calorie restriction?
The comparison ran both interventions side by side in the same experiment. Semaglutide reproduced many of the functional benefits, and on exploratory drive, spatial memory and glucose control the treated animals did better than the restricted ones.
Why only female mice?
The lifespan work was done in females. Aging interventions frequently work in one sex and not the other in mice, so the absence of male data is a real gap rather than a detail.
Should anyone take this drug for aging?
No. Semaglutide is approved for diabetes and obesity, carries real side effects, and is not approved or tested for aging in humans. Prescribing decisions belong with a doctor. This is general information rather than medical advice.